Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 144,756 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 144,756 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $679,649,358.72. This trade represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total transaction of $6,426,655.83.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The stock was sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

Shares of ROIV stock opened at $36.30 on Friday. Roivant Sciences Ltd. has a twelve month low of $11.60 and a twelve month high of $37.97. The company has a market cap of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12. The business has a fifty day simple moving average of $34.61 and a 200 day simple moving average of $30.43.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, equities research analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ROIV has been the topic of several research reports. Citigroup lifted their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright boosted their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. lifted its position in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP increased its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC raised its stake in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC lifted its holdings in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.